INOVIQ LTD. Total Liabilities
INOVIQ LTD. total liabilities. Based on the latest financial reports, INOVIQ LTD. (EGQ0) has total liabilities worth €1.72 Million EUR (≈ $2.01 Million USD) as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of INOVIQ LTD. to measure how many days the company can operate on defensive assets alone.
Total Liabilities of INOVIQ LTD. (2021–2024)
Total liabilities of INOVIQ LTD. from 2021 to 2024. This chart illustrates how INOVIQ LTD.'s total liabilities have evolved over time, based on quarterly financial data.
INOVIQ LTD. Competitors by Total Liabilities
The table below lists competitors of INOVIQ LTD. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Khind Holdings Bhd
KLSE:7062
|
Malaysia | RM126.37 Million |
|
ZOONO Group Ltd
AU:ZNO
|
Australia | AU$2.53 Million |
|
StarFlex Co. Ltd
KQ:115570
|
Korea | ₩29.18 Billion |
|
Nexgram Holdings Bhd
KLSE:0096
|
Malaysia | RM62.76 Million |
|
Purepoint Uranium Group Inc
V:PTU
|
Canada | CA$1.02 Million |
|
Xinyuan Real Estate Co Ltd
NYSE:XIN
|
USA | $4.97 Billion |
|
Lena Lighting S.A.
WAR:LEN
|
Poland | zł26.44 Million |
|
Geratherm Medical AG
XETRA:GME
|
Germany | €6.95 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down INOVIQ LTD.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see EGQ0 asset base.
Liquidity & Leverage Metrics
INOVIQ LTD. Total Liabilities Ratios Explained
INOVIQ LTD. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how INOVIQ LTD.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for INOVIQ LTD. (2021–2024)
The table below shows the annual total liabilities of INOVIQ LTD. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | €1.72 Million ≈ $2.01 Million |
-9.19% |
| 2023-06-30 | €1.89 Million ≈ $2.21 Million |
-23.86% |
| 2022-06-30 | €2.49 Million ≈ $2.91 Million |
-51.23% |
| 2021-06-30 | €5.10 Million ≈ $5.96 Million |
-- |
About INOVIQ LTD.
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non… Read more